Skip to main content
Guobang Pharma Ltd. logo

Guobang Pharma Ltd. — Investor Relations & Filings

Ticker · 605507 ISIN · CNE100004NS2 LEI · 300300PS6T4W4PGYPM51 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 510 across all filing types
Latest filing 2025-07-29 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 605507

About Guobang Pharma Ltd.

https://www.gbgcn.com

Guobang Pharma Ltd. specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and finished dosage forms. The company operates across two primary sectors: human health and animal health. Its product portfolio includes a wide range of anti-infectives, such as macrolides and quinolones, as well as cardiovascular medications and veterinary drugs like florfenicol. Guobang Pharma maintains a comprehensive industrial chain, leveraging large-scale production facilities and advanced chemical synthesis technologies to serve global markets. The organization focuses on providing integrated solutions for pharmaceutical raw materials, emphasizing quality control and regulatory compliance to meet international standards.

Recent filings

Filing Released Lang Actions
国邦医药第二届监事会第十二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the company's Supervisory Board meeting regarding the review and approval of the 2025 semi-annual report and a special report on the use of raised funds. It includes voting results and confirms compliance with legal and regulatory requirements. The document does not contain the actual financial statements or detailed financial data but refers readers to the full semi-annual report and related documents published on the stock exchange website. The document length is short (1004 characters) and serves as a meeting resolution announcement rather than the report itself. According to the 'Menu vs Meal' rule, this is an announcement about the report, not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for such announcements that do not fit other specific categories.
2025-07-29 Chinese
国邦医药2025年半年度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled "国邦医药集团股份有限公司2025 年半年度报告" which translates to "Guobang Pharma Ltd. 2025 Semi-Annual Report." It covers the period from January 1, 2025 to June 30, 2025, indicating it is a report for a period shorter than a full fiscal year. The content includes detailed financial data such as revenue, profit, cash flow, and management discussion and analysis. It also contains sections on company overview, business model, industry position, and risk factors. The document length is 15,000 characters, which is substantial and contains actual financial statements and substantive analysis. This matches the definition of an Interim / Quarterly Report (IR). It is not an announcement or a brief summary, nor is it a full annual report (10-K). Therefore, the correct classification is IR with high confidence.
2025-07-29 Chinese
国邦医药2025年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2025 年半年度报告摘要' which translates to '2025 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period, including total assets, net profit, earnings per share, and shareholder information. The document explicitly states it is a summary of the half-year report and advises investors to read the full half-year report on the official exchange website. The document length is 2745 characters, which is relatively short but contains substantive financial data and analysis for the half-year period. It is not merely an announcement or a certification but includes key financial metrics and shareholder data typical of an Interim / Quarterly Report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2025-07-29 Chinese
国邦医药第二届董事会第十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from Guobang Pharmaceutical Group Co., Ltd. It details the convening and voting results of the company's second board of directors' 14th meeting. The document mentions the approval of the 2025 semi-annual report and a special report on the use of raised funds, but it does not contain the reports themselves. Instead, it refers readers to the Shanghai Stock Exchange website for the full reports. The document is short (799 characters) and serves as an announcement of board decisions and references to other reports rather than containing substantive financial data or the reports themselves. Therefore, it fits best under Board/Management Information (MANG) as it announces board meeting resolutions and decisions.
2025-07-29 Chinese
国邦医药关于全资子公司参与设立股权投资基金完成私募投资基金备案的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Guobang Pharmaceutical Group Co., Ltd. regarding its wholly-owned subsidiary's participation in establishing an equity investment fund and the completion of the private equity fund's registration with the China Securities Investment Fund Association. It includes details about the investment, the fund's name, management, and registration date. The document is relatively short (922 characters) and serves as a formal disclosure of an investment event and regulatory filing rather than a detailed financial report or presentation. It does not contain financial statements, earnings data, or management discussion. It is an update on capital investment activity and fund registration, fitting the category of Capital/Financing Update (CAP).
2025-07-03 Chinese
国邦医药关于股份回购进展公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement from Guobang Pharmaceutical Group Co., Ltd. regarding the progress of its share repurchase program. It details the number of shares repurchased, the price range, total amount spent, and the purpose of the repurchase (employee stock ownership plan or equity incentives). The document references regulatory compliance and previous announcements about the repurchase plan. The content is focused on the update of the company's share buyback activity, which fits the category of a Transaction in Own Shares (POS). The document length is short (1243 characters), and it is not an announcement of a report publication but a substantive update on share repurchase progress. Therefore, the correct classification is POS with high confidence.
2025-07-01 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.